Name
GS2-03 - TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan (T-DXd) with or without anastrozole for HER2-low, HR+ early-stage breast cancer
Date & Time
Tuesday, December 6, 2022
Speakers
Virtual Session Link